San Francisco, California (PressExposure) January 10, 2013 -- Samir Patel, President and CEO at Ophthotech will give a keynote presentation on "A Phase 2b Study of FovistaTM, a Platelet Derived Growth Factor (PDGF) Inhibitor in Combination with a Vascular Endothelial Growth Factor (VEGF) Inhibitor for Neovascular Age-Related Macular Degeneration (AMD)" at GTC's 5th Ocular Diseases and Drug Development Conference to be held in San Francisco, CA on March 21-22, 2013.
In his presentation, Dr. Patel will assess the safety and efficacy of FovistaTM in combination with ranibizumab compared to ranibizumab monotherapy. During the trial, the combination of FovistaTM (1.5 mg) with ranibizumab met the pre-specified primary endpoint of superiority in mean visual acuity gain compared to ranibizumab monotherapy (10.6 ETDRS letters at week 24, compared to 6.5 letters, p=0.019), and enhanced visual outcomes were present at every monthly timepoint. OCT and fluorescein angiography analysis showed patients receiving FovistaTM 1.5 mg combination therapy had greater reduction in neovascular size compared to those receiving ranibizumab monotherapy. Also, no significant safety issues were observed for either treatment group in the trial.
Samir Patel is Co-founder, President and CEO of Ophthotech Corporation and serves on its Board of Directors. Previously, Dr. Patel was the co-founder of Eyetech Pharmaceuticals where he was the Chief Medical Officer and also served on its Board of Directors. Dr. Patel has been a consultant to a number of ophthalmic biotechnology companies and healthcare venture firms. In addition to Ophthotech, he currently serves on the board of directors of AFER-ARVO.
GTC's 5th Ocular Diseases and Drug Development Conference promotes the discovery of ocular disease drug development by bringing together leading scientists, researchers, and experts to discuss and collaborate on the latest research and discovery, safety assessment, and drugs in development for combating and curing age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, DME, uveitis and other eye diseases. The last annual conference was well attended by key R&D delegates GSK, Pfizer, B&L, Allergan and Alcon, and this year's conference promises to be even bigger and better.
For more information, please visit http://www.gtcbio.com